Conversely, FTO may also play an oncogenic role, as demonstrated in acute myelocytic leukaemia, where FTO is expressed at elevated levels and inhibits ASB2 and RARA gene57 by reducing transcript m6A content, resulting in enhanced cell transformation and leukaemogenesis. This evidence concerns the gene FTO and acute myeloid leukemia.